Other

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Alnylam Pharmaceuticals Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options decreased by 68.4% to $13.16M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 73.3%, from $49.37M to $13.16M. Over 4 years (FY 2021 to FY 2025), Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options shows relatively stable performance with a 0.4% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID: other_proceeds_from_issuance_of_shares_under_incentive_a_319e60

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$81.86M$72.39M$45.04M$27.12M$22.50M$153.02M$56.71M$42.37M$49.39M$24.81M$30.89M$25.86M$132.78M$108.04M$36.28M$49.37M$81.22M$77.74M$41.70M$13.16M
QoQ Change—-11.6%-37.8%-39.8%-17.0%+580.0%-62.9%-25.3%+16.6%-49.8%+24.5%-16.3%+413.5%-18.6%-66.4%+36.1%+64.5%-4.3%-46.4%-68.4%
YoY Change————-72.5%+111.4%+25.9%+56.2%+119.5%-83.8%-45.5%-39.0%+168.8%+335.5%+17.4%+90.9%-38.8%-28.0%+14.9%-73.3%
Range$13.16M – $153.02M
CAGR-31.9%
Avg YoY Growth+35.0%
Median YoY Growth+16.2%
Current Streak3 quarters decline

Frequently Asked Questions

What is Alnylam Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Alnylam Pharmaceuticals (ALNY) reported proceeds from issuance of shares under incentive and share based compensation plans including stock options of $13.16M in Q1 2026.
How has Alnylam Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options changed year-over-year?
Alnylam Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options decreased by 73.3% year-over-year, from $49.37M to $13.16M.
What is the long-term trend for Alnylam Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options has grown at a 0.4% compound annual growth rate (CAGR), from $246.27M to $250.03M.